Optimi exports MDMA capsules to Australia for PTSD care

Executive Summary

• Optimi Health Corp. completed its first export of MDMA capsules to Australia in 2026 under the Authorised Prescriber Scheme, marking a significant operational milestone for the company's psychedelic treatment initiatives.
• The initial shipment consisted of 1,000 standardized 60-milligram MDMA capsules, sufficient to support over 300 authorized PTSD treatment sessions based on standard clinical protocols.
• The export was facilitated by the completion of the company's first 2026 production cycle and the receipt of necessary import permits from Australia and export permits from Health Canada.

Key Details

• Shipment Volume and Specifications: The export included 1,000 MDMA capsules in a standardized 60-milligram dosage form.
• Clinical Capacity: The supplied quantity is sufficient to support over 300 authorized PTSD treatment sessions under MDMA-assisted therapy programs.
• Regulatory Compliance: The shipment followed the completion of Optimi's first 2026 production cycle and the receipt of required Australian import permits and Health Canada export permits.
• Data Collection: Patient-reported outcomes (PROs) are being collected by the Australian National University (ANU) to develop a comprehensive real-world evidence (RWE) data set on MDMA-assisted therapy for PTSD.
• Reimbursement Framework: The Australian Department of Veterans' Affairs (DVA) offers reimbursement for eligible veterans receiving psychedelic-assisted therapy in accordance with program requirements.
• Market Context: Approximately 5 to 6 percent of Australians experience PTSD annually, representing roughly 1.3 million to 1.5 million people, with higher prevalence among veterans and first responders.
• Manufacturing License: Optimi holds a drug establishment licence issued by Health Canada authorizing the manufacture of MDMA capsules for regulated therapeutic use.
• Distribution Partner: The company's licensed Australian pharmacy partner acts as the importer of record and national distributor, supplying authorized clinics across Australia in accordance with local regulatory requirements.